AllSight
Companies · ORKA · Pharmaceutical Preparations

Oruka Therapeutics, Inc. (ORKA)

Oruka Therapeutics, Inc. (ORKA) stock — the fundamentals (P/E, market cap, valuation) and every material event, decoded in plain English.

Oruka Therapeutics, Inc. (ORKA) stock — financials & valuation

Key numbers for Oruka Therapeutics, Inc. (ORKA): P/E ratio, market cap, profit margins, returns, and whether the stock looks cheap or expensive versus its own 5-year range.

AllSight quality score: 50/100 — a percentile rank of Oruka Therapeutics, Inc.’s fundamentals against Manufacturing peers, weakest on management. A quality ranking, not a price prediction.

Market cap$5.5B
EV / EBITDA-33.9×
Return on equity-10.3%
ROIC-18.3%
Debt / equity0.0×
Dividend yield0.0%

Independent of the events above — derived from Oruka Therapeutics, Inc.’s own financial statements and shown as context, never as advice.

Aug 24, 2026CCO appointed
Oruka hires veteran immunology commercial chief, adding launch expertise but no new milestone
Aug 10, 2026
Loss matched estimates; execution advanced, but no new clinical data arrived
Related companies in Pharmaceutical Preparations
Open live on AllSight — the whole market, decoded →

About AllSight · Editorial standards & method · Contact